Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Inclusion Criteria: * Metastatic well-to-moderately differentiated (or low-grade) neuroendocrine carcinoma, including typical carcinoid or pancreatic islet cell carcinoma. * Computerized tomography (CT) scan evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent at the time of study entry. If a CT scan is not possible, then an MRI may be used. * Patients who are currently receiving or have previously received lanreotide or another somatostatin analogue are eligible. Previous treatment with lanreotide or another somatostatin analogue is not required for study entry. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. * Adequate hematologic, hepatic and renal function. * Male patients with female partners of childbearing potential and women patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 3 months (90 days) following last dose of study drug(s). Male patients must also refrain from donating sperm during their participation in the study and for 3 months after last dose of study drug(s). * Life expectancy ≥ 3 months. * Willingness and ability to comply with study and follow-up procedures. * Ability to understand the nature of this study and give written informed consent. Exclusion Criteria: * Anti-cancer therapy with the exception of lanreotide or another somatostatin ana…